Última actualización 12 de julio de 2026
Key finding
The insulin pump therapy alone group showed a significant reduction in time to achieve glycemic targets.
This study evaluated the addition of dapagliflozin to insulin pump therapy in patients with Type 2 diabetes, finding significant improvements in glycemic targets and insulin dosage.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the addition of dapagliflozin to insulin pump therapy in patients with Type 2 diabetes, finding significant improvements in glycemic targets and insulin dosage.
These findings suggest that incorporating dapagliflozin into insulin pump therapy could enhance diabetes management by achieving glycemic targets more efficiently and reducing the overall insulin burden, which is crucial for improving patient outcomes and minimizing potential complications associated with high insulin doses.
Limited generalizability due to specific population characteristics. Potential confounding factors not measured in the study. Short duration of follow-up may not capture long-term effects.
Published in
Publication details and source links for this paper.
Miaoguan P, Yijuan X, Naifeng L, et al. The Addition of Dapagliflozin to Insulin Pump Therapy in Patients with Type 2 Diabetes. Journal of Diabetes Research. 2026;2026:9957473. doi:10.1155/jdr/9957473
Insulin pump therapy plus dapagliflozin reduced time to achieve glycemic targets by 1.2 days (p=0.01).
Total insulin dose was significantly lower by 8 units in the insulin pump therapy plus dapagliflozin group (p=0.02).
Pancreatic function improved significantly in the insulin pump therapy plus dapagliflozin group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Insulin therapy, Metformin and Assessment of pancreatic function through insulin and C-peptide levels, Time to glycemic target, Total daily insulin dose.
This study contributes evidence to
Primary intervention
Insulin therapy
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
6
Evidence pairs
137
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Insulin therapy → Assessment of pancreatic function through insulin and C-peptide levels
Insulin therapy → Assessment of pancreatic function through insulin and C-peptide levels
Insulin therapy → Time to glycemic target
Insulin therapy → Time to glycemic target
Insulin therapy → Total daily insulin dose
Insulin therapy → Total daily insulin dose
Metformin → Assessment of pancreatic function through insulin and C-peptide levels
Metformin → Assessment of pancreatic function through insulin and C-peptide levels
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and Insulin Resistance, Insulin Therapies and Assessment of pancreatic function through insulin and C-peptide levels.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Insulin Resistance
Measures Insulin Resistance as a key outcome.
All studies on Insulin Therapies
Contributes to Insulin Therapies evidence base.
All studies measuring Assessment of pancreatic function through insulin and C-peptide levels
Measures Assessment of pancreatic function through insulin and C-peptide levels as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Insulin Therapies appears to improve Insulin Resistance.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Total daily insulin dose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies appears to improve CGM Time in Range.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Time to glycemic target
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
Metformin Therapies may improve Insulin Resistance.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Total daily insulin dose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies with generally consistent results and a positive effect signal.
Limitations
Metformin Therapies may improve CGM Time in Range.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Time to glycemic target
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
